Primary human tumor xenografted models ('tumorgrafts') for good management of patients with cancer

Anti-Cancer Drugs

Volumn 22, Issue 9, 2011, Pages 827-841

  Decaudin, Didier ^a,b  

^a Department of Translational Research ^*  (France)

^b INSTITUT CURIE   (France)

Author keywords

human cancer; immunodeficient mice; tumorgraft; xenograft

Indexed keywords

MOLECULAR MARKER;

CANCER DIAGNOSIS; CANCER GRAFT; CANCER MODEL; CANCER PATIENT; CANCER REGRESSION; CANCER RELAPSE; CANCER RESISTANCE; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; CYTOGENETICS; EXPERIMENTAL DESIGN; GENE EXPRESSION; GENETIC STABILITY; GENOME ANALYSIS; HUMAN; MOLECULAR DIAGNOSIS; NONHUMAN; PATHOLOGIST; PHARMACOLOGICAL ASSESSMENT; PHARMACOLOGICAL PROCEDURES; PHENOTYPE; PRECLINICAL CANCER MODEL; PREDICTIVE VALUE; PRIORITY JOURNAL; REPRODUCIBILITY; REVIEW; SENSITIVITY ANALYSIS; SOFT TISSUE SARCOMA; TREATMENT RESPONSE; TUMOR CELL; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, SCID; NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80052472086     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3283475f70     Document Type: Review

References (90)

1. Garber K. From human to mouse and back: 'tumorgraft' models surge in popularity. J Natl Cancer Inst 2009; 101:6-8
2. Parmar H, Young P, Emerman JT, Neve RM, Dairkee S, Cunha GR. A novel method for growing human breast epithelium in vivo using mouse and human mammary fibroblasts. Endocrinology 2002; 143: 4886-4896 (Pubitemid 35397628)
3. Kuperwasser C, Chavarria T, Wu M, Magrane G, Gray JW, Carey L, et al. Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Sci U S A 2004; 101:4966-4971 (Pubitemid 38469186)
4. Sausville EA, Burger AM. Contributions of human tumor xenografts to anticancer drug development. Cancer Res 2006; 66:3351-3354
5. Peterson JK, Houghton PJ. Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur J Cancer 2004; 40:837-844 (Pubitemid 38519762)
6. Hollingshead MG. Antitumor efficacy testing in rodents. J Natl Cancer Inst 2008; 100:1500-1510.
7. Jianq Y, Kimchi ET, Staveley-O'Carroll KF, Chenq H, Ajani JA. Assessment of K-ras mutation: a step forward personalized medicine for patients with colorectal cancer. Cancer 2009; 115:3609-3617
8. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98:10869-10874 (Pubitemid 32878711)
9. Bouwman P, Jonkers J. Mouse models for BRCA1 associatedtumorigenesis: from fundamental insights to preclinical utility. Cell Cycle 2008; 7:2647-2653
10. Holstege H, Joosse SA, Van Oostrom CT, Nederlof PM, De Vries A, Jonkers J. High incidence of protein-truncating TP53 mutations in BRCA1- related breast cancer. Cancer Res 2009; 69:3625-3633
11. Hinoi T, Akyol A, Theisen BK, Ferguson DO, Greenson JK, Williams BO, et al. Mouse model of colonic adenoma-carcinoma progression based on somatic Apc inactivation. Cancer Res 2007; 67:9721-9730. (Pubitemid 47621219)
12. McCart AE, Vickaryous NK, Silver A. Apc mice: models, modifiers and mutants. Pathol Res Pract 2008; 204:479-490.
13. Oyama T, Yamada Y, Hata K, Tomita H, Hirata A, Sheng H, et al. Further upregulation of beta-catenin/Tcf transcription is involved in the development of macroscopic tumors in the colon of ApcMin/ + mice. Carcinogenesis 2008; 29:666-672 (Pubitemid 351404885)
14. Kelland LR. 'Of mice and men': values and liabilities of the thymic nude mouse model in anticancer drug development. Eur J Cancer 2004; 40:827-836 (Pubitemid 38519761)
15. Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F, De Cremoux P, et al. A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res 2007; 13:3989-3998 (Pubitemid 47037607)
16. Christgen M, Bruchhardt H, Hadamitzky C, Rudolph C, Steinemann D, Gadzicki D, et al. Comprehensive genetic and functional characterization of IPH-926: a novel CDH1-null tumour cell line from human lobular breast cancer. J Pathol 2009; 217:620-632
17. Bergamaschi A, Hjortland GO, Triulzi T, Sørlie T, Johnsen H, Ree AH, et al. Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models. Mol Oncol 2009; 3:469-482
18. Némati F, Sastre X, Laurent C, Couturier J, Mariani P, Desjardins L, et al. Development and characterization of a panel of human uveal melanoma xenografts established from primary and/or metastatic patient's tumors. Clin Cancer Res 2010; 16:2352-2362
19. Molthoff CF, Calame JJ, Pinedo HM, Boven E. Human ovarian cancer xenografts in nude mice: characterization and analysis of antigen expression. Int J Cancer 1991; 47:72-79
20. Press JZ, Kenyon JA, Xue H, Miller MA, De Luca A, Miller DM, et al. Xenografts of primary human gynaecological tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy. Gynecol Oncol 2008; 110:256-264
21. Roholl PJM, Rutgers DH, Rademakers LHPM, DeWeger RA, Elders JRJ, Van Unnik JAM. Characterization of human soft tissue sarcomas in nude mice. Am J Pathol 1988; 131:559-568
22. Loukopoulos P, Kanetaka K, Takamura M, Shibata T, Sakamoto M, Hirohashi S. Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity. Pancreas 2004; 29:193-203 (Pubitemid 39304976)
23. Rubio-Viqueira B, Jimeno A, Cusatis G, Zhang X, Iacobuzio-Donahue C, Karikari C, et al. An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res 2006; 12:4652-4661 (Pubitemid 44297818)
24. Fichtner I, Slisow W, Gill J, Becker M, Elbe B, Hillebrand T, et al. Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas. Eur J Cancer 2004; 40:297-307
25. Perez-Soler R, Kemp B, Wu QP, Mao L, Gomez J, Zeleniuch-Jacquotte A, et al. Response and determinants of sensitivity to paclitaxel in human nonsmall cell lung cancer tumors heterotransplanted in nude mice. Clin Cancer Res 2000; 6:4932-4938 (Pubitemid 32110439)
26. Bogner PN, Patnaik SK, Pitoniak R, Kannisto E, Repasky E, Hylander B, et al. Lung cancer xenografting alters microRNA profile but not immunophenotype. Biochem Biophys Res Commun 2009; 386:305-310.
27. Némati F, Bras-Gonçalves R, Fontaine JJ, De Pinieux G, De Cremoux P, Chapelier A, et al. Preclinical assessment of cisplatin-based therapy versus docetaxel in a panel of human non-small cell lung cancer xenografts. Anticancer Drugs 2009; 20:932-940.
28. Némati F, Daniel C, Arvelo F, Legrier ME, Froget B, Livartowski A, et al. Clinical relevance of human cancer xenografts as a tool for preclinical assessment : example of in vivo evaluation of topotecan-based chemotherapy in a panel of human small cell lung cancer xenografts. Anticancer Drugs 2010; 21:25-32
29. Onda K, Nagai S, Tanaka R, Morii K, Yoshimura J-I, Tsumanuma I, Kumanishi T. Establishment of two glioma cell lines from two surgical specimens obtained at different times from the same individual. J Neuro Oncol 1999; 41:247-254 (Pubitemid 29209812)
30. Borgmann A, Baldy C, Von Stackelberg A, Beyermann B, Fichtner I, Nürnberg P, et al. Childhood ALL blasts retain phenotypic and genotypic characteristics upon long-term serial passage in NOD/SCID mice. Pediat Hematol Oncol 2000; 17:635-650.
31. Lock RB, Liem N, Farnsworth ML, Milross CG, Xue C, Tajbakhsh M, et al. The nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse model of childhood acute lymphoblastic leukemia reveals intrinsic differences in biologic characteristics at diagnosis and relapse. Blood 2002; 99:4100-4108 (Pubitemid 35332053)
32. Donhuijsen K, Budach V, Van Beuningen D, Schmidt U. Instability ofxenotransplanted soft tissue sarcomas. Morphologic and flow cytometric results. Cancer 1988; 61:68-75 (Pubitemid 18023112)
33. Subramaniam MM, Navarro S, Pellin A, López-Guerrero JA, Carda C, Heredia Alvaro JA, et al. Tissue microarray profiling of primary and xenotransplanted synovial sarcomas demonstrates the immunophenotypic similarities existing between SYT-SSX fusion gene confirmed, biphasic, and monophasic fibrous variants. Virchows Arch 2006; 449:435-447 (Pubitemid 44451318)
34. Brooks JJ. The significance of double phenotype patterns and markers in human sarcomas? A new model of mesenchymal differentiation. Am J Pathol 1986; 125:113-123 (Pubitemid 17183764)
35. Taraboletti G, Giavazzi R. Modelling approaches for angiogenesis. Eur J Cancer 2004; 40:881-889 (Pubitemid 38519766)
36. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009; 324:1457-1461
37. Gong Y, Yan K, Lin F, Anderson K, Sotiriou C, Andre F, et al. Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a geneexpression profiling study. Lancet Oncol 2007; 8:203-211
38. Hu ZFC, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006; 7:96
39. Prescher G, Bornfeld N, Hirche H, Horsthemke B, Jöckel KH, Becher R. Prognostic implications of monosomy 3 in uveal melanoma. Lancet 1996; 347:1222-1225 (Pubitemid 26131850)
40. Trolet J, HupéP, Huon I, Lebigot I, Decraene C, Delattre O, et al. Genomic profiling and identification of high-risk uveal melanoma by array CGH analysis of primary tumors and liver metastases. Invest Ophthalmol Vis Sci 2009; 50:2572-2580.
41. Jeuken JWM, Sprenger SHE, Wesseling P, Bernsen HJ, Suijkerbuijk RF, Roelofs F, et al. Genetic reflection of glioblastoma biopsy material in xenografts: characterization of 11 glioblastoma xenograft lines by comparative genomic hybridization. J Neurosurg 2000; 92:652-658 (Pubitemid 30180672)
42. Claes A, Schuuring J, Boots-Sprenger S, Hendriks-Cornelissen S, Dekkers M, Van der Kogel AJ, et al. Phenotypic and genotypic characterization of orthotopic human glioma models and its relevance for the study of anti-glioma therapy. Brain Pathol 2008; 18:423-433 (Pubitemid 351782851)
43. De Plater L, LaugéA, Guyader C, Poupon M-F, Assayag F, De Cremoux P, et al. Establishment and characterization of a new breast cancer xenograft obtained from a woman carrying a germline BRCA2 mutation. Br J Cancer 2010; 103:1192-1200.
44. Reyal F, Guyader C, Decraene C, Lucchesi C, Auger N, Assayag A, et al. Molecular characterization of human breast cancer xenografts reveals a strong genomic and gene expression stability. Cancer Res 2010 AACR congress: poster presentation.
45. Indraccolo S, Tisato V, Agata S, Moserle L, Ferrari S, Callegaro M, et al. Establishment and characterization of xenografts and cancer cell cultures derived from BRCA1 -/- epithelial ovarian cancers. Eur J Cancer 2006; 42:1475-1483 (Pubitemid 43903167)
46. Houghton JA, Taylor DM. Growth characteristics of human colorectal tumours during serial passage in immune-deprived mice. Br J Cancer 1978; 37:213-223 (Pubitemid 8281320)
47. Armengol G, Knuutila S, Lluís F, CapellàG, MiróR, Caballín MR. DNA copy number changes and evaluation of MYC, IGF1R, and FES amplification in xenografts of pancreatic adenocarcinoma. Cancer Genet Cytogenet 2000; 116:133-141
48. Hoffmann J, Schmidt-Peter P, Hänsch W, Naundorf H, Bunge A, Becker M, et al. Anticancer drug sensitivity and expression of multidrug resistance markers in early passage human sarcomas. Clin Cancer Res 1999; 5:2198-2204 (Pubitemid 29399278)
49. Fiebig HH, Schuchhardt C, Henss H, Fiedler L, Löhr GW. Comparison of tumor response in nude mice and in the patients. Behring Inst Mitt 1984; 74:343-352
50. Sakamoto Y, Fujita M, Goi M, Tsukamoto F, Sugimoto T, Okuyama Y, et al. Accordance of the chemosensitivity between clinical specimens and their xenografts in nude mice by SDI test and the value of in vivo chemosensitivity test using nude mice. Gan To Kagaku Ryoho 1993; 20:447-454 (Pubitemid 23134795)
51. Harrap KR, Jones M, Siracky J, Pollard LA, Kelland LR. The establishment, characterization and calibration of human ovarian carcinoma xenografts for the evaluation of novel platinum anticancer drugs. Ann Oncol 1990; 1:65-76 (Pubitemid 20295057)
52. Singh M, Lima A, Molina R, Hamilton P, Clermont AC, Devasthali V, et al. Assessing therapeutic responses in K-ras mutant cancers using genetically engineered mouse models. Nat Biotechnol 2010; 28:585-593
53. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92:205-216 (Pubitemid 30099779)
54. Giovanella BC, Stehlin JS Jr, Shepard RC, Willians LJ Jr. Correlation between response to chemotherapy of human tumors in patients and in nude mice. Cancer 1983; 52:1146-1152 (Pubitemid 13006446)
55. Inoue K, Fujimoto S, Ogawa M. Antitumor efficacy of seventeen anticancer drugs in human breast cancer xenograft (MX-1) transplanted in nude mice. Cancer Chemother Pharmacol 1983; 10:182-186 (Pubitemid 13028317)
56. Inaba M, Kobayashi T, Tashiro T, Sakurai Y, Maruo K, Ohnishi Y, et al. Evaluation of antitumor activity in a human breast tumor/Nude mouse model with a special emphasis on treatment dose. Cancer 1989; 64:1577-1582 (Pubitemid 19251122)
57. Boven E, Winograd B, Berger DP, Dumont MP, Braakhuis BJ, Fodstad O, et al. Phase II preclinical drug screening in human tumor xenografts: a first European Multicenter Collaborative Study. Cancer Res 1992; 52:5940-5247
58. Langdon SP, Hendriks HR, Braakhuis BJ, Pratesi G, Berger DP, Fodstad O, et al. Preclinical phase II studies in human tumor xenografts: a European multicenter follow-up study. Ann Oncol 1994; 5:415-422 (Pubitemid 24159645)
59. Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti JM, Schepartz S, et al. Relationship between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 2001; 84:1424-1431 (Pubitemid 32522115)
60. Voskoglou-Nomikos T, Pater JL, Seymour L. Clinical predictive value of the in vitro cell lines, human xenograft, and mouse allograft preclinical cancermodels. Clin Cancer Res 2003; 9:4227-4239 (Pubitemid 37204044)
61. Taetle R, Rosen F, Abramson I, Venditti J, Howell S. Use of nude mouse xenografts as preclinical drug screens: in vivo activity of established chemotherapeutic agents against melanoma and ovarian carcinoma xenografts. Cancer Treat Rep 1987; 71:297-304 (Pubitemid 17051732)
62. Némati F, Livartowski A, De Cremoux P, Bourgeois Y, Arvelo F, Pouillart P, et al. Distinctive potentiating effects of cisplatin and/or ifosfamide combined with etoposide in human small cell lung carcinoma xenografts. Clin Cancer Res 2000; 6:2075-2086 (Pubitemid 30305108)
63. Jimeno A, Solomon A, Karikari C, Garrido-Laguna I, Trusty D, Hruban R, et al. A prospective validation of a direct tumor xenograft model in pancreatic ductal adenocarcinoma (PDA).Chicago, IL: ASCO Annual Meeting; 2008; 26 [Abstract 4500].
64. Bellet RE, Danna V, Mastrangelo MJ, Berd D. Evaluation of a 'nude' mousehuman tumor panel as a predictive secondary screen for cancer chemotherapy agents. J Natl Cancer Inst 1979; 63:1185-1187
65. Maruo K, Ueyama Y, Inaba M, Emura R, Ohnishi Y, Nakamura O, et al.Responsiveness of subcutaneous human glioma xenografts to various antitumor agents. Anticancer Res 1990; 10:209-212
66. Inaba M, Tashiro T, Kobayashi T, Sakurai Y, Maruo K, Ohnishi Y, et al. Responsiveness of human gastric tumors implanted in nude mice to clinically equivalent doses of various antitumor agents. Jpn J Cancer Res 1988; 79:517-522
67. Thompson J, Zamboni WC, Cheshire PJ, Lutz L, Luo X, Li Y, et al. Efficacy of systemic administration of irinotecan against neuroblastoma xenografts. Clin Cancer Res 1997; 3:423-432
68. Kerbel RS. Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans. Cancer Biol Ther 2003; 2:S134-S139
69. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007; 13:2329-2334 (Pubitemid 46698581)
70. Zalcman G, Monnet I, Vaylet F, Livartowski A, Cadranel J, Poupon MF, et al. VP16-Ifosfamide, a non-platinum-containing combination for extensive smallcell lung cancer (SCLC): a phase II French, open single-arm multicentric trial. International Association for the Study of Lung Cancer-13th World Conference on Lung Cancer 2009 [Poster P2228].
71. Fiebig HH, Maier A, Burger AM. Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. Eur J Cancer 2004; 40:802-820. (Pubitemid 38519759)
72. Rubio-Viqueira B, Hidalgo M. Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients. Clin Pharmacol Ther 2009; 82:217-221
73. Rosol TJ, Tannelli-Gregg SH, LeRoy BE, Mandl S, Contag CH. Animal models of bone metastasis. Cancer 2003; 97:748-757 (Pubitemid 36125810)
74. Yang H, Jager MJ, Grossniklaus HE. Bevacizumab suppresses establishment of micrometastases in experimental ocular melanoma. Invest Ophthalmol Vis Sci 2010; 51:2835-2842
75. Man S, Munoz R, Kerbel RS. On the development of models in mice of advanced visceral metastatic disease for anti-cancer drug testing. Cancer Metastasis rev 2007; 26:737-747 (Pubitemid 350115117)
76. Corti C, Pratesi G, DeCesare M, Pellegrini R, Giardini R, Supino R, et al. Spontaneous lung metastases in a human lung tumor xenograft: a new experimental model. J Cancer Res Clin Oncol 1996; 122:154-160. (Pubitemid 26076886)
77. Eccles SA, Box G, Court W, Sandle J, Dean CJ. Preclinical models for the evaluation of targeted therapies of metastatic disease. Cell Biophys 1994; 24-25:279-291
78. Howard RB, Mullen JB, Pagura ME, Johnston MR. Characterization of a highly metastatic, orthotopic lung cancer model in the nude rat. Clin Exp Metastasis 1999; 17:157-162 (Pubitemid 29335442)
79. Nemeth JA, Harb JF, Barroso U Jr, He Z, Grignon DJ, Cher ML. Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone. Cancer Res 1999; 59:1987-1993 (Pubitemid 29186176)
80. Yonou H, Yokose T, Kamijo T, Kanomata N, Hasebe T, Nagai K, et al. Establishment of a novel species- and tissue-specific metastasis model of human prostate cancer in humanized non-obese diabetic/severe combined immunodeficient mice engrafted with human adult lung and bone. Cancer Res 2001; 61:2177-2182 (Pubitemid 32692044)
81. Lu X, Wang Q, Hu G, Van Poznak C, Fleisher M, Reiss M, et al. ADAMTS1 and MMP proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. Genes Dev 2009; 23: 1882-1894
82. Marangoni E, Lecomte N, Durand L, De Pinieux G, Decaudin D, Chomienne C, et al. CD44 targeting reduces tumor growth and prevents post-chemotherapy relapse of human breast cancers xenografts. Br J Cancer 2009; 100:918-922
83. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA 2009; 106:13820-13825
84. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100:3983-3988 (Pubitemid 36418143)
85. Legrier ME, De Pinieux G, Poirson-Bichat F, Apiou F, Dutrillaux AM, Boye K, et al. A new model of human prostate cancer, the PAC120 xenograft. Pathol Biol (Paris) 2003; 51:1-4 (Pubitemid 36367886)
86. Legrier ME, De Pinieux G, Boye K, Arvelo F, Judde JG, Fontaine JJ, et al. Mucinous differentiation features associated with hormonal escape in a human prostate cancer xenograft. Br J Cancer 2004; 90:720-727 (Pubitemid 38297216)
87. Legrier ME, Guyader C, Ceraline J, Dutrillaux B, Oudard S, Poupon MF, et al. Hormone escape is associated with genomic instability in a human prostate cancer model. Int J Cancer 2009; 124:1103-1111
88. Legrier ME, Oudard S, Judde JG, Guyader C, De Pinieux G, Boye K, et al. Potentiation of antitumour activity of docetaxel by combination with trastuzumab in a human prostate cancer xenograft model and underlying mechanisms. Br J Cancer 2007; 96:269-276 (Pubitemid 46160632)
89. Oudard S, Legrier ME, Boye K, Bras-Goncalves R, De Pinieux G, De Cremoux P, et al. Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts. J Urol 2003; 169: 1729-1734 (Pubitemid 36443482)
90. Dahmani A, De Plater L, Guyader C, Fontaine JJ, Berniard A, Assayag F, et al. A preclinical therapeutic schedule optimizing docetaxel plus estramustine administration in prostate cancers. Anticancer Drugs 2010; 21:927-931